PE20140162A1 - Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol - Google Patents

Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol

Info

Publication number
PE20140162A1
PE20140162A1 PE2013002121A PE2013002121A PE20140162A1 PE 20140162 A1 PE20140162 A1 PE 20140162A1 PE 2013002121 A PE2013002121 A PE 2013002121A PE 2013002121 A PE2013002121 A PE 2013002121A PE 20140162 A1 PE20140162 A1 PE 20140162A1
Authority
PE
Peru
Prior art keywords
diol
octyl
propane
phenyl
ethyl
Prior art date
Application number
PE2013002121A
Other languages
English (en)
Inventor
Supriya Rane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140162(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20140162A1 publication Critical patent/PE20140162A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN MODULADOR DEL RECEPTOR ESFINGOSINA-1-FOSFATO (S1P) TAL COMO 2-AMINO-2-[2-(4-OCTIL-FENIL)-ETIL]-PROPANO-1,3-DIOL (FINGOLIMOD) EN UNA CANTIDAD DEL 1.5% O MENOS EN PESO DE LA COMPOSICION; B) UN RELLENO TAL COMO MANITOL; C) UN AGLUTINANTE TAL COMO HIDROXI-PROPIL-CELULOSA; D) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO; Y E) UN ESTABILIZANTE TAL COMO HIDROXI-PROPIL-BETA-CICLODEXTRINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE
PE2013002121A 2011-04-01 2012-03-30 Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol PE20140162A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11

Publications (1)

Publication Number Publication Date
PE20140162A1 true PE20140162A1 (es) 2014-02-12

Family

ID=45953284

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013002121A PE20140162A1 (es) 2011-04-01 2012-03-30 Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol
PE2017000900A PE20170913A1 (es) 2011-04-01 2012-03-30 Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017000900A PE20170913A1 (es) 2011-04-01 2012-03-30 Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol

Country Status (35)

Country Link
US (5) US9592208B2 (es)
EP (2) EP2694037B1 (es)
JP (1) JP6019101B2 (es)
KR (1) KR102027014B1 (es)
CN (1) CN103476400B (es)
AR (1) AR085749A1 (es)
AU (1) AU2012236357B2 (es)
BR (1) BR112013024430B1 (es)
CA (1) CA2831600C (es)
CL (1) CL2013002810A1 (es)
CO (1) CO6771459A2 (es)
CY (2) CY1118423T1 (es)
DK (2) DK3143990T3 (es)
EA (2) EA027721B1 (es)
EC (1) ECSP13012912A (es)
ES (2) ES2773482T3 (es)
GT (1) GT201300227A (es)
HK (1) HK1190309A1 (es)
HR (2) HRP20170021T1 (es)
HU (1) HUE031286T2 (es)
IL (1) IL228250B (es)
JO (1) JO3177B1 (es)
LT (2) LT2694037T (es)
MA (1) MA34981B1 (es)
MX (1) MX342522B (es)
MY (2) MY163746A (es)
PE (2) PE20140162A1 (es)
PL (2) PL3143990T3 (es)
PT (2) PT3143990T (es)
RS (1) RS59917B1 (es)
SG (1) SG193256A1 (es)
SI (2) SI3143990T1 (es)
TW (1) TWI528958B (es)
WO (1) WO2012135561A1 (es)
ZA (1) ZA201306636B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
AU2016209466A1 (en) * 2015-01-20 2017-08-10 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
CA2213989C (en) 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4153563B2 (ja) 1997-02-27 2008-09-24 ノバルティス アーゲー 医薬組成物
DK1002792T3 (da) 1997-04-04 2004-11-22 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
EP2316431B1 (en) 2003-04-08 2015-09-30 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PL3103448T3 (pl) * 2006-09-26 2019-12-31 Novartis Ag Kompozycje farmaceutyczne zawierające modulator S1P
EP2120575A4 (en) 2006-12-21 2011-04-27 Abbott Lab AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
PT2952177T (pt) 2007-10-12 2021-04-26 Novartis Ag Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p)
NZ591999A (en) 2008-11-11 2013-06-28 Novartis Ag Salts of fingolimod fty720
PL3409274T3 (pl) 2008-12-22 2020-06-01 Novartis Ag Schemat dawkowania dla agonisty receptora s1p

Also Published As

Publication number Publication date
US9592208B2 (en) 2017-03-14
EA201790436A2 (ru) 2017-10-31
CN103476400A (zh) 2013-12-25
DK2694037T3 (en) 2017-01-16
MX342522B (es) 2016-10-03
ES2773482T3 (es) 2020-07-13
ZA201306636B (en) 2014-05-28
US20180193291A1 (en) 2018-07-12
US20200276137A1 (en) 2020-09-03
CN103476400B (zh) 2016-11-09
CL2013002810A1 (es) 2014-02-14
AR085749A1 (es) 2013-10-23
PL3143990T3 (pl) 2020-05-18
MA34981B1 (fr) 2014-03-01
KR20140014194A (ko) 2014-02-05
US20190247335A1 (en) 2019-08-15
MX2013011415A (es) 2013-12-09
JP2014509652A (ja) 2014-04-21
EP2694037A1 (en) 2014-02-12
IL228250B (en) 2020-09-30
PT3143990T (pt) 2020-03-04
KR102027014B1 (ko) 2019-09-30
PL2694037T3 (pl) 2017-05-31
HUE031286T2 (hu) 2017-06-28
RS59917B1 (sr) 2020-03-31
EP2694037B1 (en) 2016-10-12
LT3143990T (lt) 2020-02-25
EA201391442A1 (ru) 2014-04-30
CY1118423T1 (el) 2017-06-28
PE20170913A1 (es) 2017-07-12
TW201244711A (en) 2012-11-16
US20140371323A1 (en) 2014-12-18
HK1190309A1 (zh) 2014-07-04
BR112013024430B1 (pt) 2022-02-08
CO6771459A2 (es) 2013-10-15
LT2694037T (lt) 2017-01-10
AU2012236357A1 (en) 2013-10-10
TWI528958B (zh) 2016-04-11
SG193256A1 (en) 2013-10-30
CA2831600C (en) 2020-04-21
AU2012236357B2 (en) 2016-03-10
BR112013024430A2 (pt) 2016-12-20
EA027721B1 (ru) 2017-08-31
ES2610966T3 (es) 2017-05-04
CY1122868T1 (el) 2021-05-05
CA2831600A1 (en) 2012-10-04
ECSP13012912A (es) 2013-11-29
JO3177B1 (ar) 2018-03-08
DK3143990T3 (da) 2020-03-02
GT201300227A (es) 2015-05-05
SI2694037T1 (sl) 2017-01-31
NZ615023A (en) 2016-07-29
HRP20200249T1 (hr) 2020-05-15
MY175633A (en) 2020-07-02
EA035686B1 (ru) 2020-07-27
WO2012135561A1 (en) 2012-10-04
PT2694037T (pt) 2017-01-17
MY163746A (en) 2017-10-31
EP3143990A1 (en) 2017-03-22
US20170135967A1 (en) 2017-05-18
JP6019101B2 (ja) 2016-11-02
HRP20170021T1 (hr) 2017-03-10
EA201790436A3 (ru) 2018-03-30
SI3143990T1 (sl) 2020-03-31
EP3143990B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
PE20140162A1 (es) Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol
PE20120337A1 (es) Producto conteniendo formas de dosificacion oral de fingolimod
BR112015014753A2 (pt) composições, utilização de uma composição, método para o combate dos fungos fitopatogênicos e semente
CO6270342A2 (es) Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
BR112015016722A2 (pt) óleo de máquina de refrigeração e composição de fluido de trabalho para máquina de refrigeração
BR112014018032A2 (pt) método para produzir uma composição
BR112015011430A2 (pt) composição para liberação imediata e prolongada
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
CO6592108A2 (es) Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
CO2018003459A2 (es) Composiciones para el cuidado bucal que comprenden fosfato de zinc y un agente antimicrobiano
BR112014007177A2 (pt) agente antifúngico
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
BR112014030992A2 (pt) composições compreendendo calcogenetos e métodos relacionados
PE20142247A1 (es) Proceso para mejorar la eficiencia de alimentacion y caracteristicas de la canal de los animales
PE20150632A1 (es) Composicion farmaceutica que tiene fluidez mejorada, agente medicional, y metodo para la produccion y uso del mismo
UY35059A (es) Método y composición para el tratamiento de ectoparásitos
TN2013000425A1 (en) Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
AR124661A2 (es) Formulaciones
BR112014005626A2 (pt) combinações compreendendo um modulador do receptor de s1p

Legal Events

Date Code Title Description
FG Grant, registration